CorMedix Announces Positive Phase III Results for REZZAYO in Stem Cell Transplant Prophylaxis

Key Points and Investor Highlights

• CorMedix Therapeutics (NASDAQ: CRMD) has reported positive topline results from the global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases (IFDs) in adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
• Primary Endpoint Met: The ReSPECT study met its primary endpoint of fungal-free survival at Day 90, demonstrating non-inferiority versus the standard antimicrobial regimen (SAR). Fungal-free survival rates were 60.7% for rezafungin compared to 59.0% for SAR.
• Safety and Tolerability: Rezafungin was well tolerated, with a safety profile comparable to SAR. Importantly, the study showed a favorable benefit in toxicity-related discontinuations and drug-drug interactions, positioning rezafungin as a safer alternative especially for immunocompromised patients.
• Comparable Efficacy: The trial demonstrated comparable efficacy against invasive infections from Candida, Aspergillus, and Pneumocystis in both treatment arms, as well as similar rates of overall mortality.
• Secondary Endpoints: The results highlighted positive differentiation in key safety-related secondary endpoints, including fewer treatment emergent adverse events leading to dose reduction, interruption, or withdrawal of the study drug.
• Regulatory Pathway: CorMedix and partners anticipate a pre-NDA meeting with the FDA in the coming months, targeting a supplemental New Drug Application (sNDA) submission in the second half of 2026 based on the ReSPECT results.
• Market Opportunity: CorMedix estimates that the potential U.S. market opportunity for REZZAYO in prophylaxis exceeds \$2 billion, supported by orphan drug exclusivity through 2035 and patent protection until 2038.
• Commercial Rights: Mundipharma sponsors the clinical trial and holds commercial rights to rezafungin outside the U.S., while Melinta Therapeutics, a wholly-owned subsidiary of CorMedix, manages U.S. distribution.
• Forward-Looking Statements: The company notes risks associated with regulatory approval, market adoption, competition, and clinical trial outcomes.

Detailed Analysis for Investors

CorMedix’s announcement of positive topline data from the ReSPECT trial marks a pivotal moment for the company and its shareholders. The trial, one of the largest global multicenter, randomized, double-blind studies for antifungal prophylaxis, evaluated the efficacy and safety of once-weekly rezafungin compared to standard antimicrobial regimens in a high-risk, immunocompromised population. This population experiences prolonged immunosuppression and is highly vulnerable to invasive fungal diseases, making effective and safe prophylactic therapies critical.

The study achieved its primary endpoint, a crucial regulatory milestone for both the FDA and EMA, by demonstrating non-inferiority in fungal-free survival rates at Day 90. This suggests that rezafungin’s differentiated pharmacokinetic/pharmacodynamic profile is as effective as current standards, with the added advantage of improved tolerability.

For shareholders, the most price-sensitive information is the strong positioning of REZZAYO for a potential expanded indication in antifungal prophylaxis. The data not only supports comparable efficacy but also highlights a safety advantage in terms of reduced toxicity and drug-drug interactions. If approved, this could accelerate adoption in clinical practice and expand the addressable market significantly.

The company’s estimate of a \$2 billion U.S. market opportunity, backed by orphan drug status and extended patent protection, underscores the potential for substantial revenue growth. Moreover, the anticipated sNDA submission in 2H26 sets a clear regulatory timeline, providing investors with visibility on key upcoming catalysts.

The partnership structure is also noteworthy: Mundipharma retains commercial rights outside the U.S., while CorMedix, through Melinta Therapeutics, focuses on U.S. distribution. This arrangement could enable rapid commercialization upon regulatory approval.

The press release contains standard forward-looking statements, highlighting risks including regulatory hurdles, market adoption challenges, competition, intellectual property expiration, and possible changes in trial outcomes as more data becomes available. Investors should monitor these risks closely.

Conclusion

The positive results from the ReSPECT Phase III trial for REZZAYO represent a significant value inflection point for CorMedix. The combination of efficacy, safety, regulatory progress, and large market potential makes this news highly relevant for investors and likely to impact share value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information is based on public disclosures by CorMedix and is subject to change. Investors should conduct their own due diligence and consult with financial advisors prior to making any investment decisions. Past performance and projections are not indicative of future results.

View CorMedix Inc. Historical chart here